{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:34:35Z","timestamp":1790393675670,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"DOI":"10.1038\/s44276-024-00087-1","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T11:01:44Z","timestamp":1727780504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CNS prophylaxis is (mostly) futile in DLBCL"],"prefix":"10.1038","volume":"2","author":[{"given":"Kevin","family":"Shieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Brem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"87_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/annonc\/mdl327","volume":"18","author":"V Boehme","year":"2007","unstructured":"Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfeundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18:149\u201357. https:\/\/doi.org\/10.1093\/annonc\/mdl327.","journal-title":"Ann Oncol."},{"key":"87_CR2","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS international prognostic index: a risk model for cns relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150\u20136. https:\/\/doi.org\/10.1200\/JCO.2015.65.6520.","journal-title":"J Clin Oncol"},{"key":"87_CR3","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1002\/cncr.25278","volume":"116","author":"JS Abramson","year":"2010","unstructured":"Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takorian T, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116:4283\u201390. https:\/\/doi.org\/10.1002\/cncr.25278.","journal-title":"Cancer."},{"key":"87_CR4","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v116\u201325. https:\/\/doi.org\/10.1093\/annonc\/mdv304.","journal-title":"Ann Oncol"},{"key":"87_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/bjh.16866","volume":"190","author":"P McKay","year":"2020","unstructured":"McKay P, Wilson MR, Chaganti S, Smith J, Fox CP, Cwynarski K. The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper. Br J Haematol. 2020;190:708\u201314. https:\/\/doi.org\/10.1111\/bjh.16866.","journal-title":"Br J Haematol"},{"key":"87_CR6","unstructured":"Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL et al. NCCN Guidelines, B-Cell Lymphomas. Version 02.2024."},{"key":"87_CR7","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2021014506","volume":"139","author":"MR Wilson","year":"2022","unstructured":"Wilson MR, Eyre TA, Kirkwood AA, Doo NW, Soussain C, Choquet S, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood. 2022;139:2499\u2013511. https:\/\/doi.org\/10.1182\/blood.2021014506.","journal-title":"Blood"},{"key":"87_CR8","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/bjc.2014.405","volume":"111","author":"CY Cheah","year":"2014","unstructured":"Cheah CY, Herbert KE, O\u2019Rourke K, Kennedy GA, George A, Fedele PL, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111:1072\u20139.","journal-title":"Br J Cancer"},{"key":"87_CR9","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1200\/JCO.23.00365","volume":"41","author":"KL Lewis","year":"2023","unstructured":"Lewis KL, Jakobsen LH, Villa D, Smedby KE, Savage KJ, Eyre TA, et al. International CNS prophylaxis study group. High-dose methotrexate as CNS prophylaxis in high-risk aggressive B-cell lymphoma. J Clin Oncol. 2023;41:5376\u201387.","journal-title":"J Clin Oncol"},{"key":"87_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ajh.26181","volume":"96","author":"R Puckrin","year":"2021","unstructured":"Puckrin R, El Darsa H, Ghosh S, Peters A, Owen C, Stewart D. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma. Am J Hematol. 2021;96:764\u201371. https:\/\/doi.org\/10.1002\/ajh.26181.","journal-title":"Am J Hematol"},{"key":"87_CR11","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/annonc\/mds621","volume":"24","author":"H Holte","year":"2013","unstructured":"Holte H, Lepp\u00e4 S, Bj\u00f6rkholm M, Fluge O, Jyrkkio S, Delabie J, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell\/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013;24:1385\u201392.","journal-title":"Ann Oncol"},{"key":"87_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood.2021012888","volume":"139","author":"VM Orellana-Noia","year":"2022","unstructured":"Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek M, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139:413\u201323. https:\/\/doi.org\/10.1182\/blood.2021012888.","journal-title":"Blood"},{"key":"87_CR13","doi-asserted-by":"publisher","first-page":"e60026bd","DOI":"10.1097\/01.HS9.0000967828.60026.bd","volume":"7","author":"SA Yahng","year":"2023","unstructured":"Yahng SA, Yhim HY, Kwak JY, Shin HJ, Moon JH, Eom HS, et al. S229: prophylactic efficacy of intrathecal versus intravenous methotrexate for CNS relapse in high-risk diffuse large B cell lymphoma: a phase III randomized, controlled study. Hemasphere. 2023;7:e60026bd https:\/\/doi.org\/10.1097\/01.HS9.0000967828.60026.bd.","journal-title":"Hemasphere"},{"key":"87_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/hematology.2022000331","volume":"2022","author":"MR Wilson","year":"2022","unstructured":"Wilson MR, Bobillo S, Cwynarski K. CNS prophylaxis in aggressive B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2022;2022:138\u201345. https:\/\/doi.org\/10.1182\/hematology.2022000331.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"87_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.clml.2023.06.008","volume":"23","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Liu Z, Gao C, Bian H, Ma Y, Jing F, et al. Role of rituximab in treatment of patients with primary central nervous system lymphoma (PCNSL): a systematic review and meta-analysis. Clin Lymph Myeloma Leuk. 2023;23:733\u201341.","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"87_CR16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","volume":"21","author":"D Villa","year":"2010","unstructured":"Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21:1046\u201352.","journal-title":"Ann Oncol"},{"key":"87_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2021-149644","volume":"1238","author":"JA Mutter","year":"2021","unstructured":"Mutter JA, Ali S, Lauer EM, Esfahani MS, Mitschke J, Kurtz DM, et al. Profiling of circulating tumor DNA for noninvasive disease detection, risk stratification, and MRD monitoring in patients with CNS lymphoma. Blood. 2021;1238:6.","journal-title":"Blood"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00087-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00087-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00087-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T11:07:44Z","timestamp":1727780864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00087-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["87"],"URL":"https:\/\/doi.org\/10.1038\/s44276-024-00087-1","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EB has participated in Speakers Bureaus for BeiGene, Astra Zeneca, SeaGen, Incyte\/Morphosys, and GenMab\/AbbVie.\u00a0She has provided consultancy for Caribou Biosciences, Genetech, Morphosys, BeiGene, ADC Therapeutics, and Astra Zeneca. EB is a member of the Editorial Board of this journal.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}